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Background
The European AIDS Clinical Society (EACS) Guidelines have since 2005 provided
multidisciplinary recommendations for the care of HIV-positive persons in geographically diverse
areas.
Guideline highlights
Major revisions have been made in all sections of the 2017 Guidelines: antiretroviral treatment
(ART), comorbidities, coinfections and opportunistic diseases. Newly added are also a summary of
the main changes made, and direct video links to the EACS online course on HIV Management.
Recommendations on the clinical situations in which tenofovir alafenamide may be considered
over tenofovir disoproxil fumarate are provided, and recommendations on which antiretrovirals
can be used safely during pregnancy have been revised. Renal and bone toxicity and hepatitis C
virus (HCV) treatment have been added as potential reasons for ART switches in fully
virologically suppressed individuals, and dolutegravir/rilpivirine has been included as a treatment
option. In contrast, dolutegravir monotherapy is not recommended. New recommendations on
non-alcoholic fatty liver disease, chronic lung disease, solid organ transplantation, and
prescribing in elderly are included, and human papilloma virus (HPV) vaccination
recommendations have been expanded. All drug–drug interaction tables have been updated and
new tables are included. Treatment options for direct-acting antivirals (DAAs) have been updated
and include the latest combinations of sofosbuvir/velpatasvir/voxilaprevir and glecaprevir/
pibrentasvir. Recommendations on management of DAA failure and acute HCV infection have
been expanded. For treatment of tuberculosis (TB), it is underlined that intermittent treatment is
contraindicated, and for resistant TB new data suggest that using a three-drug combination may
be as effective as a five-drug regimen, and may reduce treatment duration from 18-24 to
6-10 months.
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Conclusions
Version 9.0 of the EACS Guidelines provides a holistic approach to HIV care and is translated into
the six most commonly spoken languages.
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The European AIDS Clinical Society (EACS)
Guidelines
The European AIDS Clinical Society (EACS) Guidelines
were revised in 2017 for the 12th time (including interim
updates) since the Guidelines were first developed in 2005
[1]. The Guidelines aim to cover a relatively large and
diverse area geographically, with very different national
levels of access to care. As a natural consequence, the EACS
Guidelines provide a wider range of recommendations than
the often much more uniform national guidelines. The aims
of the EACS Guidelines to provide easily accessible and
comprehensive multidisciplinary recommendations to clin-
icians involved in the care of HIV-positive individuals have
previously been described in detail [2].
Major revisions have been made in all main sections:
visit assessment, antiretroviral treatment (ART), comorbidi-
ties, coinfections and opportunistic diseases. Newly intro-
duced in version (v.) 9.0 is a section summarizing the main
changes made since the release of the last interim update
(v.8.2) of the Guidelines. In previous years, this summary
page was only available online on the EACS website, but it
is now included in the Guidelines themselves.
Also new in the 2017 version are direct video links to the
EACS online course on HIV Management. These links can
be found throughout the Guidelines in the respective sec-
tions and collated on the last page of the Guidelines. There
is no need to register or to sign in as the online courses are
freely available for all by simply clicking the video link.
The EACS Guidelines v.9.0 have been translated into
the six most commonly spoken languages, Spanish,
Portuguese, French, Russian, German and Chinese, and
are available online (www.eacsociety.org/guidelines/eacs-
guidelines/eacs-guidelines.html), in print as a booklet and
as a free app for iOS and Android devices produced with
the Sanford Group.
The Guidelines group warmly welcome comments on
the Guidelines, which can be submitted via guideli-
nes@eacsociety.org.
The review process
The EACS Guidelines undergo systematic minor
revisions annually and major systematic revisions
biennially. Additional interim updates make it possible
to incorporate any new important data in a timely
fashion, and ensure that the Guidelines remain up to
date.
Each section of the Guidelines is managed by a panel
of European HIV experts and additional experts where
relevant (e.g. a cardiologist, oncologist and pulmonologist
in the Comorbidity section) (see Appendix 1). Details of
the Guidelines management have been reported previ-
ously [2].
The Guidelines are extensively cross-reviewed by the
panel members with input from representatives from
Women against Viruses in Europe (WAVE) and the com-
munity. EACS further collaborates with linguists, design-
ers, app developers and translators to produce the three
final versions of the Guidelines.
In the following sections, the most important changes
made in 2017 for each section of the Guidelines are
described in more detail.
ART section
Only drugs currently licensed by the European Medicines
Agency (EMA) are taken into consideration in the Guide-
lines. The EACS Guidelines continue to recommend six
preferred ART regimens for ART-na€ıve adults: four inte-
grase inhibitor (INSTI)-based, one nonnucleoside reverse
transcriptase inhibitor (NNRTI)-based, and one ritonavir/
cobicistat (COBI)-boosted protease inhibitor (PI/r or PI/
c)-based (Table 1). As alternative regimens, to be used
when none of the preferred regimens are feasible or
available, seven options are currently recommended: one
INSTI-based, two NNRTI-based, three boosted PI-based
and one combining raltegravir (RAL) and boosted daru-
navir (DRV/r or DRV/c). The alternative regimens are
ordered by preference of use, whereas the preferred regi-
mens are considered equally effective. The older PI/r
lopinavir/r was this year removed from the list of alter-
native suggested PIs.
Added in 2017 is an expert recommendation on the
clinical situations in which use of tenofovir alafenamide
(TAF) may be considered over tenofovir disoproxil fuma-
rate (TDF), while still acknowledging that long-term fol-
low-up data on TAF is pending.
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Table 1 Initial combination regimens for antiretroviral therapy (ART)-na€ıve adult HIV-positive persons. (A) Recommended regimens (one of
the following to be selected)*,†. (B) Alternative regimens (to be used when none of the preferred regimens are feasible or available, whatever
the reason)
A
Regimen Dosing Caution
Food
requirement
2 NRTIs + INSTI
ABC/3TC/DTG‡,§ ABC/3TC/DTG 600/300/50 mg,
1 tablet qd
Al/Ca/Mg-containing antacids or
multivitamins should be taken
well separated in time
(minimum 2 h after or 6 h
before)
None
TAF/FTC¶ or
TDF/FTC¶
TAF/FTC 25/200 mg, 1 tablet qd or
TDF/FTC 300/200 mg, 1 tablet qd
None
+DTG +DTG 50 mg, 1 tablet qd DTG 50 mg bid with rifampicin
TAF/FTC/EVG/c¶ or
TDF/FTC/EVG/c¶,**
TAF/FTC/EVG/c 10/200/150/150 mg,
1 tablet qd or
TDF/FTC/EVG/c 300/200/150/150 mg,
1 tablet qd
Al/Ca/Mg-containing antacids or
multivitamins should be taken
well separated in time
(minimum 2 h after or 6 h
before)
With food
TAF/FTC¶ or TDF/FTC¶ TAF/FTC 25/200 mg, 1 tablet qd or
TDF/FTC 300/200 mg, 1 tablet qd
Co-administration of antacids
containing Al or Mg not
recommended. RAL 400 or
800 mg bid with rifampicin
None
+RAL +RAL 400 mg, 1 tablet bid
2 NRTIs + NNRTI
TAF/FTC/RPV¶ or
TDF/FTC/RPV¶
TAF/FTC/RPV 25/200/25 mg, 1
tablet qd or
TDF/FTC/RPV 300/200/25 mg,
1 tablet qd
Only if CD4 count > 200 cells/lL
and HIV-VL < 100 000 copies/mL.
PPI contraindicated; H2
antagonists to be taken 12 h
before or 4 h after RPV
With food
2 NRTIs + PI/r or PI/c
TAF/FTC¶ or
TDF/FTC¶
TAF/FTC 10/200 mg, 1 tablet qd or
TDF/FTC 300/200 mg, 1 tablet qd
Monitor in persons with a known
sulfonamide allergy
With food
+DRV/c†† or
+DRV/r††
DRV/c 800/150 mg, 1 tablet qd or
+DRV 800 mg, 1 tablet qd + RTV
100 mg, 1 tablet qd
B
Regimen Dosing Caution
Food
requirement
2 NRTIs + INSTI
ABC/3TC‡,§+RAL ABC/3TC 600/300 mg, 1 tablet qd + RAL 400 mg, 1 tablet bid Co-administration of antacids containing
Al or Mg not recommended.
RAL 400 or 800 mg bid with rifampicin
None
2 NRTIs + NNRTI
ABC/3TC‡,§ + EFV‡‡ ABC/3TC 600/300 mg, 1 tablet qd + EFV 600 mg, 1 tablet qd Only if HIV-VL < 100 000 copies/mL At bed time
or 2 h
before
dinner
TDF/FTC/EFV¶,‡‡ TDF/FTC/EFV 300/200/600 mg, 1 tablet qd
2 NRTIs + PI/r or PI/c
TAF/FTC¶ or TDF/FTC¶ TAF/FTC 10/200 mg 1 tablet qd or
TDF/FTC 300/200 mg, 1 tablet qd
With food
+ATV/c§§,¶¶
or +ATV/r§§,¶¶
+ATV/c 300/150 mg, 1 tablet qd or
+ATV 300 mg, 1 tablet qd + RTV 100 mg,
1 tablet qd
ABC/3TC‡,§
+ATV/c§§,¶¶
or +ATV/r§§,¶¶
ABC/3TC 600/300 mg, 1 tablet qd
+ATV/c 300/150 mg 1 tablet qd or
+ATV 300 mg, 1 tablet qd + RTV 100 mg,
1 tablet qd
Only if HIV-VL < 100 000 copies/mL With food
ABC/3TC‡,§
+DRV/c†† or
+DRV/r††
ABC/3TC 600/300 mg, 1 tablet qd
+DRV/c 800/150 mg, 1 tablet qd or
+DRV 800 mg, 1 tablet qd + RTV 1
tablet 100 mg, 1 tablet qd
Monitor in persons with a known
sulfonamide allergy
With food
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The antiretrovirals considered safe to use during preg-
nancy have been revised, and now also include efavirenz,
RAL, dolutegravir (DTG), rilpivirine (RPV) and DRV/r. As
there is still limited experience with TAF and COBI in preg-
nancy, these are not recommended as part of initial regi-
mens. In the case of a women becoming pregnant while on
COBI-boosted elvitegravir (EVG/c), closer monitoring of
HIV viral load and drug levels may be necessary, as data
from pharmacokinetic studies have found substantially
lower levels of EVG/c during pregnancy, which may not be
adequate for sustained viral suppression [3,4]. ART con-
taining an INSTI is recommended in women starting treat-
ment in the late second or third trimester to ensure a rapid
reduction in viral load. The Guidelines advise against
breast feeding. However, if breast feeding is still carried
out, it is recommended to increase clinical and virological
monitoring of both the mother and the infant.
Renal and bone toxicity and ongoing hepatitis C virus
(HCV) treatment have been added as additional reasons
for performing drug switches in virologically suppressed
individuals. For class-sparing options, DTG and RPV have
been added as additional options, as has lamivudine
(3TC) used in combination with either boosted DRV or
atazanavir (ATV). DTG monotherapy is not recommended.
Safety data from the D:A:D study suggesting a cumula-
tive association between use of boosted DRV and incident
cardiovascular disease have also been included [5].
Comorbidity section
Entirely new sections on non-alcoholic fatty liver disease
(NAFLD), chronic lung disease, solid organ transplantation,
and prescribing in elderly have been added in v.9.0,
acknowledging the increased prevalence of each of these
conditions, and the need for HIV-specific guidance to deal
with multimorbidity and potential drug–drug interactions.
In the renal section, an additional dynamic measure of
renal impairment (rapid progression of renal function) has
been included to allow for earlier detection of worsening
renal function. Different scenarios of prevalent or high risk
of renal impairment in which TAF may be used over TDF
are specified, as has also been done in the bone section.
Acknowledging new recommendations in the general
population, blood pressure targets have been lowered to
systolic pressure < 130 and diastolic pressure < 80 mmHg
for individuals at high risk, for example diabetics, where
resources allow. There are, however, still limited data on
cardiovascular disease prevention related to the use of
oral antidiabetics in HIV-positive persons, and the current
management recommendations have been updated to
include various combinations of metformin together with
other antidiabetics. In HIV-positive persons inadequately
controlled on maximum statin doses or intolerant to
statins, PCSK9 inhibitors, a new lipid-lowering drug class,
may be used.
Table 1 (Continued )
B
Regimen Dosing Caution
Food
requirement
Other combinations
RAL§
+DRV/c†† or
+DRV/r††
RAL 400 mg, 1 tablet bid
+DRV/c 800/150 mg, 1 tablet qd or
+DRV 800 mg, 1 tablet qd + RTV 100 mg,
1 tablet qd
Only if CD4 count > 200 cells/lL and HIV-VL
< 100 000 copies/mL. Co-administration of
antacids containing Al or Mg not recommended
With food
*Only drugs currently licensed for initiation of therapy by the EMA are taken into consideration (in alphabetical order).
†Generic HIV drugs are becoming more available and can be used as long as they replace the same drug and do not break recommended fixed dose
combinations.
‡ABC contraindicated if HLA-B*5701 positive. Even if HLA-B*5701 negative, counselling on HSR risk still mandatory. ABC should be used with caution
in persons with a high CVD risk (> 20%).
§Use this combination only if HBsAg-negative.
¶In certain countries TDF is labelled as 245 mg rather than 300 mg to reflect the concentration of the active metabolite (tenofovir disoproxil). When
available, combinations containing TDF can be replaced by the same combinations containing TAF, TAF is used at 10 mg when co-administered with
drugs that inhibit P-gp, and at 25 mg when co-administered with drugs that do not inhibit P-gp. The decision whether to use TDF or TAF depends on
individual characteristics as well as availability. So far, there are only limited long-term data on TAF. TAF*** should be considered as a first choice****
over TDF in individuals with: established or high risk of CKD; co-medication with nephrotoxic drugs or prior TDF toxicity; osteoporosis/progressive
osteopenia or risk factors; history of fragility fracture. ***There are limited data on use of TAF with eGFR < 30 mL/min; **** Expert opinion pending
clinical data.
**TDF/FTC/EVG/c use only if eGFR ≥ 70 mL/min. It is recommended that TDF/FTC/EVG/c is not initiated in persons with eGFR < 90 mL/min unless this is
the preferred treatment.
††A single study has shown increase in CVD risk with cumulative use of DRV [13].
‡‡EFV: not to be given if history of suicide attempts or mental illness; not active against HIV-2 and HIV-1 group O strains.
§§Co-administration of PPI is contraindicated. If PPI co-administration is judged unavoidable, consider an alternative regimen; if given, dose increase
of ATV to 400 mg qd may be considered, close clinical monitoring is recommended and doses of PPI comparable to omeprazole 20 mg should not be
exceeded and must be taken approximately 12 h prior to the ATV/r. H2 antagonists to be taken 12 h before or 4 h after ATV.
¶¶Potential renal toxicity with ATV/r and ATV/c.
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In the vaccination section, human papilloma virus
(HPV) vaccination recommendations have been expanded
to include vaccination of all HIV-positive persons up to
the age of 26 years, or 40 years in the case of men who
have sex with men, with three doses of the 9-valent vac-
cine. The vaccination effect is, however, questionable in
the case of already prevalent HPV infection.
The current screening recommendation for anal cancer
has been extended to also include persons with evidence
of HPV-related dysplasia. Also, for cervical cancer, the
screening recommendation has been expanded to include
all HIV-positive women within 1 year after sexual debut
or > 21 years of age.
Screening for hepatocellular carcinoma (HCC) is indi-
cated in all persons with cirrhosis, regardless of the
underlying reason. Screening should also be performed
systematically in persons without cirrhosis with hepatitis
B virus (HBV) coinfection at high HCC risk (i.e. a family
history) or with chronic hepatitis.
Drug–drug interaction tables
The drug–drug interaction tables in the EACS Guidelines
provide an overview of the potential for interactions
between individual antiretroviral drugs and the most
commonly used comedications within a therapeutic area.
All drug–drug interaction tables in v.9.0 have been
updated with the addition of COBI-boosted atazanavir
(ATV/c) which has been licensed since the last Guidelines
update.
Entirely new drug–drug interaction tables have addi-
tionally been included on drugs used for treating chronic
lung disease and pulmonary hypertension and immuno-
suppressants used in solid organ transplantation.
Changes to the existing tables include a strong recom-
mendation against the coadministration of potent steroids
with boosted regimens because of the increased risk of
developing Cushing syndrome.
Also, the contraceptive table has been updated to
include various contraceptive methods to better discrimi-
nate between drug–drug interactions associated with a
risk of contraceptive failure and those unlikely to impair
efficacy.
Detailed information on drug–drug interactions can be
found at the University of Liverpool website: www.hiv-
druginteractions.org.
Coinfection section
In the coinfection section, details on older regimens used
for treating HCV coinfection including ribavirin (RBV)
and interferon (IFN) have been removed altogether as
they are no longer considered standard of care. Previous
versions of the Guidelines (e.g. v.8.2) with details on
IFN/RBV can, however, still be found online (www.eacsoc
iety.org/guidelines/guidelines-archive/archive.html) [6].
Treatment for HCV with direct-acting antivirals (DAAs)
should be considered for everyone coinfected with HIV
regardless of fibrosis stage, and the treatment section has
been updated to include information on the latest
approved pangenotypic drugs vosevi (combination of
sofosbuvir, velpatasvir and voxilaprevir) and maviret
(glecaprevir and pibrentasvir) recommended (Table 2).
Use of boceprevir and telaprevir is no longer recom-
mended because of high rates of adverse drug reactions
and insufficient cure rates.
The table of drug–drug interactions between individual
DAAs and antiretrovirals has also been updated with the
newest drugs and remains important because of the
potentially deleterious interactions between DAAs and
certain boosted PIs or NNRTIs.
Recommendations for DAA treatment failure manage-
ment have been further extended to include specifications
of possible drug combinations, treatment duration and
resistance testing.
The algorithm for management of acute HCV infection
has been revised with a focus on risk reduction, treatment
of concomitant sexually transmitted infections and con-
siderations of short DAA treatment and enrolment in
clinical trials.
As the optimal treatment duration for HBV infection
remains unknown, current expert opinion suggests life-
long treatment.
Added to the 2017 version are also recommendations
to include TDF or TAF for all HBV surface anti-
gen (HBsAg)-positive coinfected persons treated with
chemotherapy or other immunosuppressive therapies.
Similarly, all anti-HBc-positive persons treated with sev-
ere immunosuppressive therapies should be treated with
TDF/TAF-containing ART to prevent HBV reactivation.
Opportunistic diseases section
Based on the findings of the REALITY trial [7], which was
performed in sub-Saharan African countries, recommen-
dations on enhanced infection prophylaxis in severely
immunosuppressed individuals (CD4 count < 50 cells/lL)
with isoniazid for 12 weeks, fluconazole 100 mg/day for
12 weeks, azithromycin 500 mg/day for 5 days and a
single dose of albendazole 400 mg in addition to
trimethoprim/sulfamethoxazole have been added to
decrease risks of all opportunistic infections, including
cryptococcal meningitis, and mortality. In countries
where flucytosine is not available, fluconazole 400 mg
© 2018 The Authors.
HIV Medicine Published by John Wiley & Sons Ltd on behalf of British HIV Association
HIV Medicine (2018)
Highlights of 2017 EACS Guidelines 5
twice a day (bid) has been added as a possible alternative
in combination with liposomal amphotericin B during the
induction phase for cryptococcal meningitis.
In the section on tuberculosis (TB) management, it is
underlined that intermittent TB treatment (i.e. two to
three times weekly) is contraindicated in HIV-positive
persons.
A recommendation has been added to consider supple-
mentary steroid therapy to prevent IRIS in individuals
treated for active TB starting ART [8].
For resistant (MDR/XDR) TB, preliminary data from the
Nix trail [9] suggest that using a three-drug combination
(pretomanid, bedaquiline and linezolid) may be as effec-
tive as a five-drug regimen, and may reduce treatment
duration from 18–24 to 6–10 months.
In persons with latent TB, a 9-month treatment
duration with isoniazid is recommended in countries
with a high TB prevalence. For treating resistant
latent TB, regimens have to be chosen on an individual
basis.
Among the preferred treatment options for cerebral
toxoplasmosis, intravenous trimethoprim/sulfamethoxa-
zole has been added as a treatment option when oral
administration is not possible.
Conclusions
The revised v.9.0 of the EACS Guidelines has been
updated in collaboration with a large team of HIV and
external experts and is available online, as a free app,
and as a booklet. The 2017 version provides a holistic
approach to HIV care, aims to cover a diverse geographi-
cal area and is translated into Spanish, Portuguese,
French, Russian, German and Chinese.
Table 2 Hepatitis C virus (HCV) treatment options in HCV/HIV-coinfected persons
IFN-free HCV treatment options
HCV GT Treatment regimen
Treatment duration & RBV usage
Non-cirrhotic Compensated cirrhotic Decompensated cirrhotics CTP class B/C
1 & 4 SOF + SMP  RBV GT 4 only: 12 weeks with RBV or 24 weeks without RBV* Not recommended
SOF/LDV  RBV 8 weeks without RBV† or 12 weeks RBV‡ 12 weeks with RBV§
SOF + DCV  RBV 12 weeks  RBV‡ 12 weeks with RBV§
SOF/VEL 12 weeks 12 weeks with RBV
SOF/VEL/VOX 8 weeks‡‡ 12 weeks Not recommended
OBV/PTV/r + DSV 8¶-12 weeks in GT 1b 12 weeks in GT 1b Not recommended
OBV/PTV/r + DSV + RBV 12 weeks in GT 1a 24 weeks in GT 1a Not recommended
OBV/PTV/r + RBV 12 weeks in GT 4 Not recommended
EBR/GZR 12 weeks** Not recommended
GLE/PIB 8 weeks 12 weeks Not recommended
2 SOF + DCV 12 weeks 12 weeks with RBV
SOF/VEL 12 weeks 12 weeks with RBV
SOF/VEL/VOX 8 weeks‡‡ 12 weeks Not recommended
GLE/PIB 8 weeks 12 weeks Not recommended
3 SOF + DCV  RBV 12 weeks  RBV†† or 24 weeks without RBV 24 weeks with RBV
SOF/VEL  RBV 12 weeks  RBV†† or 24 weeks without RBV 24 weeks with RBV
SOF/VEL/VOX 8 weeks‡‡ Not recommended
GLE/PIB 8 weeks§§ 12 weeks§§ Not recommended
5 & 6 SOF/LDV  RBV 12 weeks  RBV or 24 weeks without RBV* 12 weeks with RBV§
SOF + DCV  RBV 12 weeks  RBV or 24 weeks without RBV* 12 weeks with RBV§
SOF/VEL 12 weeks 12 weeks with RBV
SOF/VEL/VOX 8 weeks‡‡ 12 weeks Not recommended
GLE/PIB 8 weeks 12 weeks Not recommended
DCV, daclatasvir; DSV, dasabuvir; EBR, elbasvir; GLE, glecaprevir; GZR, grazoprevir; LDV, ledipasvir; OBV, ombitasvir; PIB, pibrentasvir; PTV/r, paritaprevir/
RTV; RBV, ribavirin; SMP, simeprevir; SOF, sofosbuvir; VEL, velpatasvir; VOX, voxilaprevir; RAS, resistance associated substitutions.
*In treatment experienced persons RBV treatment for 12 weeks or prolong treatment to 24 weeks without RBV.
†8 weeks treatment without RBV only in treatment-na€ıve persons with F < 3 and baseline HCV-RNA < 6 million IU/mL.
‡Addition of RBV in GT1a treatment experienced persons, but not in persons without NS5A RASs, if RASs testing is available.
§In persons intolerant to RBV, treatment may be prolonged to 24 weeks. RBV can be omitted in treatment-na€ıve or -experienced persons with com-
pensated cirrhosis without baseline NS5A RAS.
¶8 weeks treatment without RBV only in persons without cirrhosis.
**Extension of treatment to 16 weeks and addition of RBV in persons with GT1a with baseline HCV-RNA > 800.000 IU/mL and NS5A RASs and in HCV
GT4 experienced persons with HCV-RNA > 800.000 IU/mL.
††Addition of RBV only in treatment experienced persons with baseline NS5A RASs, if RAS testing available; if these persons are intolerant to RBV,
treatment may be prolonged to 24 weeks without RBV.
‡‡Extension of treatment to 12 weeks in DAA treatment experienced persons.
§§Treatment duration in HCV GT3 who failed previous treatment with IFN and RBV  SOF or SOF and RBV should be 16 weeks.
© 2018 The Authors.
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Appendix 1
Panel members
The EACS Medical Secretariat is responsible for the coor-
dination and updating of the EACS Guidelines based on
the recommendations from the four EACS panels.
Guidelines Chair and Coordinator: Manuel Battegay,
Basel, Switzerland.
Assistant Coordinator: Lene Ryom, Copenhagen, Den-
mark.
HIV treatment
Chair: Anton Pozniak, London, UK.
Vice-Chair: Jose Arribas, Madrid, Spain.
Young Scientist: Margherita Bracchi, London, UK.
Panel members: Antonella d’Arminio Monforte, Milan,
Italy; Manuel Battegay, Basel, Switzerland; Nathan Clu-
meck, Brussels, Belgium; Nikos Dedes, Athens, Greece;
Jose M. Gatell, Barcelona, Spain; Andrzej Horban, War-
saw, Poland; Christine Katlama, Paris, France; Jens D.
Lundgren, Copenhagen, Denmark; Sheena McCormack,
London, UK; Jean-Michel Molina, Paris, France; Cristina
Mussini, Modena, Italy; Francois Raffi, Nantes, France;
Peter Reiss, Amsterdam, the Netherlands; Hans-J€urgen
Stellbrink, Hamburg, Germany.
Comorbidities
Chair: Georg Behrens, Hannover, Germany.
Vice-Chair: Patrick Mallon, Dublin, Ireland.
Young scientist: Lene Ryom, Copenhagen, Denmark.
Panel members: Manuel Battegay, Basel, Switzerland;
Mark Bower, London, UK; Paola Cinque, Milan, Italy;
Simon Collins, London, UK; Juliet Compston, Cambridge,
UK; Stephane De Wit, Brussels, Belgium; Leonardo M.
Fabbri, Modena, Italy; Christoph A. Fux, Aarau,
Switzerland; Giovanni Guaraldi, Modena, Italy; Jens D.
Lundgren, Copenhagen, Denmark; Esteban Martınez,
Barcelona, Spain; Catia Marzolini, Basel, Switzerland;
Socrates Papapoulos, Leiden, the Netherlands; Renaud du
Pasquier, Lausanne, Switzerland; Neil Poulter, London,
UK; Peter Reiss, Amsterdam, the Netherlands; Ian
Williams, London, UK; Alan Winston, London, UK.
Coinfections
Chair: Massimo Puoti, Milan, Italy.
Vice-Chair: Andri Rauch, Bern, Switzerland.
Young scientist: Christoph Boesecke, Bonn, Germany.
Panel members: Juan Berenguer, Madrid, Spain; Sanjay
Bhagani, London, UK; Raffaele Bruno, Pavia, Italy; Svilen
Konov, London, UK; Karine Lacombe, Paris, France; Ste-
fan Mauss, D€usseldorf, Germany; Luıs Mend~ao, Lisbon,
Portugal; Lars Peters, Copenhagen, Denmark; J€urgen K.
Rockstroh, Bonn, Germany.
Opportunistic infections
Chair: Jose M. Miro, Barcelona, Spain.
Vice-Chair: Ole Kirk, Copenhagen, Denmark.
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